TY - JOUR AU - Chen, W. AU - Zheng, R. AU - Baade, P. D. AU - Zhang, S. AU - Zeng, H. AU - Bray, F. PY - 2016 DA - 2016// TI - Cancer statistics in China, 2015 JO - CA Cancer J Clin VL - 66 UR - https://doi.org/10.3322/caac.21338 DO - 10.3322/caac.21338 ID - Chen2016 ER - TY - JOUR AU - Islami, F. AU - Chen, W. AU - Yu, X. Q. AU - Lortet-Tieulent, J. AU - Zheng, R. AU - Flanders, W. D. PY - 2017 DA - 2017// TI - Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013 JO - Ann Oncol VL - 28 ID - Islami2017 ER - TY - JOUR AU - Heigener, D. F. AU - Reck, M. PY - 2018 DA - 2018// TI - Advanced non-small cell lung cancer: the role of PD-L1 inhibitors JO - J Thorac Dis VL - 10 UR - https://doi.org/10.21037/jtd.2018.01.112 DO - 10.21037/jtd.2018.01.112 ID - Heigener2018 ER - TY - JOUR AU - Reck, M. AU - Rodriguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csoszi, T. AU - Fulop, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Rittmeyer, A. AU - Barlesi, F. AU - Waterkamp, D. AU - Park, K. AU - Ciardiello, F. AU - Pawel, J. PY - 2017 DA - 2017// TI - Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial JO - Lancet. VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)32517-X DO - 10.1016/S0140-6736(16)32517-X ID - Rittmeyer2017 ER - TY - JOUR AU - Grigg, C. AU - Rizvi, N. A. PY - 2016 DA - 2016// TI - PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction JO - Journal for immunotherapy of cancer VL - 4 UR - https://doi.org/10.1186/s40425-016-0153-x DO - 10.1186/s40425-016-0153-x ID - Grigg2016 ER - TY - JOUR AU - Aguiar, P. N. AU - Mello, R. A. AU - Hall, P. AU - Tadokoro, H. AU - Lima Lopes, G. PY - 2017 DA - 2017// TI - PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data JO - Immunotherapy. VL - 9 UR - https://doi.org/10.2217/imt-2016-0150 DO - 10.2217/imt-2016-0150 ID - Aguiar2017 ER - TY - JOUR AU - Dempke, W. C. M. AU - Fenchel, K. AU - Dale, S. P. PY - 2018 DA - 2018// TI - Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree? JO - Translational lung cancer research VL - 7 UR - https://doi.org/10.21037/tlcr.2018.04.18 DO - 10.21037/tlcr.2018.04.18 ID - Dempke2018 ER - TY - JOUR AU - Diggs, L. P. AU - Hsueh, E. C. PY - 2017 DA - 2017// TI - Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response JO - Biomarker research VL - 5 UR - https://doi.org/10.1186/s40364-017-0093-8 DO - 10.1186/s40364-017-0093-8 ID - Diggs2017 ER - TY - JOUR AU - Kleppe, M. AU - Levine, R. L. PY - 2014 DA - 2014// TI - Tumor heterogeneity confounds and illuminates: assessing the implications JO - Nat Med VL - 20 UR - https://doi.org/10.1038/nm.3522 DO - 10.1038/nm.3522 ID - Kleppe2014 ER - TY - JOUR AU - Hirsch, F. R. AU - McElhinny, A. AU - Stanforth, D. AU - Ranger-Moore, J. AU - Jansson, M. AU - Kulangara, K. PY - 2017 DA - 2017// TI - PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.11.2228 DO - 10.1016/j.jtho.2016.11.2228 ID - Hirsch2017 ER - TY - JOUR AU - Shien, K. AU - Papadimitrakopoulou, V. A. AU - Wistuba, I. I. PY - 2016 DA - 2016// TI - Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer JO - Lung Cancer VL - 99 UR - https://doi.org/10.1016/j.lungcan.2016.06.016 DO - 10.1016/j.lungcan.2016.06.016 ID - Shien2016 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science. VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Tang, H. AU - Wang, Y. AU - Chlewicki, L. K. AU - Zhang, Y. AU - Guo, J. AU - Liang, W. PY - 2016 DA - 2016// TI - Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade JO - Cancer Cell VL - 29 UR - https://doi.org/10.1016/j.ccell.2016.02.004 DO - 10.1016/j.ccell.2016.02.004 ID - Tang2016 ER - TY - JOUR AU - Dong, Z. Y. AU - Wu, S. P. AU - Liao, R. Q. AU - Huang, S. M. AU - Wu, Y. L. PY - 2016 DA - 2016// TI - Potential biomarker for checkpoint blockade immunotherapy and treatment strategy JO - Tumour Biol VL - 37 UR - https://doi.org/10.1007/s13277-016-4812-9 DO - 10.1007/s13277-016-4812-9 ID - Dong2016 ER - TY - STD TI - Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2017. ID - ref17 ER - TY - JOUR AU - Luksza, M. AU - Riaz, N. AU - Makarov, V. AU - Balachandran, V. P. AU - Hellmann, M. D. AU - Solovyov, A. PY - 2017 DA - 2017// TI - A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy JO - Nature. VL - 551 UR - https://doi.org/10.1038/nature24473 DO - 10.1038/nature24473 ID - Luksza2017 ER - TY - JOUR AU - Yarchoan, M. AU - Hopkins, A. AU - Jaffee, E. M. PY - 2017 DA - 2017// TI - Tumor mutational burden and response rate to PD-1 inhibition JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMc1713444 DO - 10.1056/NEJMc1713444 ID - Yarchoan2017 ER - TY - JOUR AU - Goodman, A. M. AU - Kato, S. AU - Bazhenova, L. AU - Patel, S. P. AU - Frampton, G. M. AU - Miller, V. PY - 2017 DA - 2017// TI - Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0386 DO - 10.1158/1535-7163.MCT-17-0386 ID - Goodman2017 ER - TY - JOUR AU - Hellmann, M. D. AU - Callahan, M. K. AU - Awad, M. M. AU - Calvo, E. AU - Ascierto, P. A. AU - Atmaca, A. PY - 2018 DA - 2018// TI - Tumor mutational burden and efficacy of Nivolumab monotherapy and in combination with Ipilimumab in small-cell lung Cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.04.001 DO - 10.1016/j.ccell.2018.04.001 ID - Hellmann2018 ER - TY - JOUR AU - Hellmann, M. D. AU - Ciuleanu, T. E. AU - Pluzanski, A. AU - Lee, J. S. AU - Otterson, G. A. AU - Audigier-Valette, C. PY - 2018 DA - 2018// TI - Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801946 DO - 10.1056/NEJMoa1801946 ID - Hellmann2018 ER - TY - JOUR AU - Lek, M. AU - Karczewski, K. J. AU - Minikel, E. V. AU - Samocha, K. E. AU - Banks, E. AU - Fennell, T. PY - 2016 DA - 2016// TI - Analysis of protein-coding genetic variation in 60,706 humans JO - Nature. VL - 536 UR - https://doi.org/10.1038/nature19057 DO - 10.1038/nature19057 ID - Lek2016 ER - TY - JOUR AU - Koboldt, D. C. AU - Zhang, Q. AU - Larson, D. E. AU - Shen, D. AU - McLellan, M. D. AU - Lin, L. PY - 2012 DA - 2012// TI - VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing JO - Genome Res VL - 22 UR - https://doi.org/10.1101/gr.129684.111 DO - 10.1101/gr.129684.111 ID - Koboldt2012 ER - TY - JOUR AU - Wang, K. AU - Li, M. AU - Hakonarson, H. PY - 2010 DA - 2010// TI - ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data JO - Nucleic Acids Res VL - 38 UR - https://doi.org/10.1093/nar/gkq603 DO - 10.1093/nar/gkq603 ID - Wang2010 ER - TY - JOUR AU - Fehrenbacher, L. AU - Spira, A. AU - Ballinger, M. AU - Kowanetz, M. AU - Vansteenkiste, J. AU - Mazieres, J. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial JO - Lancet. VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00587-0 DO - 10.1016/S0140-6736(16)00587-0 ID - Fehrenbacher2016 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients JO - Nature. VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Zhu, J. AU - Armstrong, A. J. AU - Friedlander, T. W. AU - Kim, W. AU - Pal, S. K. AU - George, D. J. PY - 2018 DA - 2018// TI - Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond JO - Journal for Immunotherapy of Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0314-1 DO - 10.1186/s40425-018-0314-1 ID - Zhu2018 ER - TY - JOUR AU - Ilie, M. AU - Long-Mira, E. AU - Bence, C. AU - Butori, C. AU - Lassalle, S. AU - Bouhlel, L. PY - 2016 DA - 2016// TI - Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv489 DO - 10.1093/annonc/mdv489 ID - Ilie2016 ER - TY - JOUR AU - Ren, S. AU - Tian, Q. AU - Amar, N. AU - Yu, H. AU - Rivard, C. J. AU - Caldwell, C. PY - 2018 DA - 2018// TI - The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression JO - Lung Cancer VL - 125 UR - https://doi.org/10.1016/j.lungcan.2018.09.004 DO - 10.1016/j.lungcan.2018.09.004 ID - Ren2018 ER - TY - JOUR AU - Li, W. AU - Song, P. AU - Guo, L. AU - Liu, X. AU - Guo, C. AU - Ying, J. PY - 2019 DA - 2019// TI - Clinical significance of >/= 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients JO - Thoracic cancer VL - 10 ID - Li2019 ER - TY - JOUR AU - Pan, Y. AU - Zheng, D. AU - Li, Y. AU - Cai, X. AU - Zheng, Z. AU - Jin, Y. PY - 2017 DA - 2017// TI - Unique distribution of programmed death ligand 1 (PD-L1) expression in east Asian non-small cell lung cancer JO - J Thorac Dis VL - 9 UR - https://doi.org/10.21037/jtd.2017.08.61 DO - 10.21037/jtd.2017.08.61 ID - Pan2017 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Sundar, R. AU - Soong, R. AU - Cho, B. C. AU - Brahmer, J. R. AU - Soo, R. A. PY - 2014 DA - 2014// TI - Immunotherapy in the treatment of non-small cell lung cancer JO - Lung Cancer VL - 85 UR - https://doi.org/10.1016/j.lungcan.2014.05.005 DO - 10.1016/j.lungcan.2014.05.005 ID - Sundar2014 ER - TY - JOUR AU - Lu, J. AU - Lee-Gabel, L. AU - Nadeau, M. C. AU - Ferencz, T. M. AU - Soefje, S. A. PY - 2015 DA - 2015// TI - Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy JO - J Oncol Pharm Pract VL - 21 UR - https://doi.org/10.1177/1078155214538087 DO - 10.1177/1078155214538087 ID - Lu2015 ER - TY - JOUR AU - Chen, C. L. AU - Pan, Q. Z. AU - Zhao, J. J. AU - Wang, Y. AU - Li, Y. Q. AU - Wang, Q. J. PY - 2016 DA - 2016// TI - PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma JO - Oncoimmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2016.1176653 DO - 10.1080/2162402X.2016.1176653 ID - Chen2016 ER - TY - JOUR AU - Fusi, A. AU - Festino, L. AU - Botti, G. AU - Masucci, G. AU - Melero, I. AU - Lorigan, P. PY - 2015 DA - 2015// TI - PD-L1 expression as a potential predictive biomarker JO - The Lancet Oncology VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00307-1 DO - 10.1016/S1470-2045(15)00307-1 ID - Fusi2015 ER - TY - JOUR AU - Yeo, M. K. AU - Choi, S. Y. AU - Seong, I. O. AU - Suh, K. S. AU - Kim, J. M. AU - Kim, K. H. PY - 2017 DA - 2017// TI - Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma JO - Hum Pathol VL - 68 UR - https://doi.org/10.1016/j.humpath.2017.08.016 DO - 10.1016/j.humpath.2017.08.016 ID - Yeo2017 ER - TY - JOUR AU - Sun, J. M. AU - Zhou, W. AU - Choi, Y. L. AU - Choi, S. J. AU - Kim, S. E. AU - Wang, Z. PY - 2016 DA - 2016// TI - Prognostic significance of PD-L1 in patients with non-small cell lung Cancer: a large cohort study of surgically resected cases JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.04.007 DO - 10.1016/j.jtho.2016.04.007 ID - Sun2016 ER - TY - JOUR AU - Yarchoan, M. AU - Johnson, B. A. AU - Lutz, E. R. AU - Laheru, D. A. AU - Jaffee, E. M. PY - 2017 DA - 2017// TI - Targeting neoantigens to augment antitumour immunity JO - Nat Rev Cancer VL - 17 UR - https://doi.org/10.1038/nrc.2016.154 DO - 10.1038/nrc.2016.154 ID - Yarchoan2017 ER - TY - JOUR AU - Goodman, A. M. AU - Kato, S. AU - Cohen, P. R. AU - Boichard, A. AU - Frampton, G. AU - Miller, V. PY - 2018 DA - 2018// TI - Genomic landscape of advanced basal cell carcinoma: implications for precision treatment with targeted and immune therapies JO - Oncoimmunology. VL - 7 UR - https://doi.org/10.1080/2162402X.2017.1404217 DO - 10.1080/2162402X.2017.1404217 ID - Goodman2018 ER - TY - JOUR AU - Chalmers, Z. R. AU - Connelly, C. F. AU - Fabrizio, D. AU - Gay, L. AU - Ali, S. M. AU - Ennis, R. PY - 2017 DA - 2017// TI - Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden JO - Genome Med VL - 9 UR - https://doi.org/10.1186/s13073-017-0424-2 DO - 10.1186/s13073-017-0424-2 ID - Chalmers2017 ER - TY - JOUR AU - Madore, J. AU - Strbenac, D. AU - Vilain, R. AU - Menzies, A. M. AU - Yang, J. Y. AU - Thompson, J. F. PY - 2016 DA - 2016// TI - PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1714 DO - 10.1158/1078-0432.CCR-15-1714 ID - Madore2016 ER - TY - JOUR AU - Scheel, A. H. AU - Ansen, S. AU - Schultheis, A. M. AU - Scheffler, M. AU - Fischer, R. N. AU - Michels, S. PY - 2016 DA - 2016// TI - PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations JO - Oncoimmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2015.1131379 DO - 10.1080/2162402X.2015.1131379 ID - Scheel2016 ER - TY - JOUR AU - Carbone, D. P. AU - Reck, M. AU - Paz-Ares, L. AU - Creelan, B. AU - Horn, L. AU - Steins, M. PY - 2017 DA - 2017// TI - First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1613493 DO - 10.1056/NEJMoa1613493 ID - Carbone2017 ER - TY - JOUR AU - Hellmann, M. D. AU - Rizvi, N. A. AU - Goldman, J. W. AU - Gettinger, S. N. AU - Borghaei, H. AU - Brahmer, J. R. PY - 2017 DA - 2017// TI - Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study JO - The Lancet Oncology VL - 18 UR - https://doi.org/10.1016/S1470-2045(16)30624-6 DO - 10.1016/S1470-2045(16)30624-6 ID - Hellmann2017 ER -